What was really interesting to me is the exchange didn't even matter. It was a pink sheet stock in bankruptcy. You can't get much worse. It just shows that a biotech balance sheet and financials mean absolutely nothing after an FDA approval. I'm sure their accountants had all the going out of business disclaimers in the filings. lol
From your link:
The news, coming during Ovarian Cancer Awareness Month, sent the stock of Fremont-based Vermillion (Pink Sheets: VRMLQ.PK) from 5 cents per share to $1.29 — a 2,587 percent increase.
So, on good news, clsn shouldn't have any difficulty doubling.
In Reply to 'ME2012' Thanks 4 your response. I did a quick search and found this article on the company. I am sure there are other cases as well
Market Data 
Markets 
AI
